Vanguard Group
INMB icon

Vanguard Group’s INmune Bio INMB Stock Holding History

Vanguard Group’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.49M Buy
957,846
+81,554
+9% +$146K ﹤0.01% 3654
2025
Q3 		$1.81M Buy
876,292
+28,541
+3% +$65.3K ﹤0.01% 3609
2025
Q2 		$1.96M Buy
847,751
+21,138
+3% +$155K ﹤0.01% 3538
2025
Q1 		$6.46M Buy
826,613
+88,412
+12% +$702K ﹤0.01% 3072
2024
Q4 		$3.45M Buy
738,201
+17,489
+2% +$91.2K ﹤0.01% 3401
2024
Q3 		$3.88M Buy
720,712
+92,413
+15% +$657K ﹤0.01% 3365
2024
Q2 		$5.54M Buy
628,299
+86,970
+16% +$857K ﹤0.01% 3215
2024
Q1 		$6.36M Hold
541,329
– – ﹤0.01% 3196
2023
Q4 		$6.1M Sell
541,329
-9,251
-2% -$77.5K ﹤0.01% 3202
2023
Q3 		$3.73M Hold
550,580
– – ﹤0.01% 3369
2023
Q2 		$5M Buy
550,580
+8,937
+2% +$71.8K ﹤0.01% 3304
2023
Q1 		$3.5M Hold
541,643
– – ﹤0.01% 3468
2022
Q4 		$3.43M Buy
541,643
+245
+0% +$1.74K ﹤0.01% 3464
2022
Q3 		$3.36M Sell
541,398
-12,240
-2% -$107K ﹤0.01% 3523
2022
Q2 		$4.89M Hold
553,638
– – ﹤0.01% 3385
2022
Q1 		$4.66M Buy
553,638
+42,609
+8% +$383K ﹤0.01% 3569
2021
Q4 		$5.21M Buy
511,029
+62,118
+14% +$920K ﹤0.01% 3587
2021
Q3 		$8.72M Buy
448,911
+69,743
+18% +$1.35M ﹤0.01% 3325
2021
Q2 		$6.66M Buy
379,168
+65,948
+21% +$889K ﹤0.01% 3425
2021
Q1 		$3.72M Buy
313,220
+60,289
+24% +$1.09M ﹤0.01% 3673
2020
Q4 		$4.36M Buy
252,931
+46,236
+22% +$435K ﹤0.01% 3424
2020
Q3 		$2.13M Buy
+206,695
New +$2.1M ﹤0.01% 3469

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Vanguard Group's INMB Position: Q4 2025 in Review

Vanguard Group increased its INmune Bio (INMB) stake by 9.3% in Q4 2025, buying an estimated $146K and bringing the position to 957,846 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #3654.

Vanguard Group first reported a position in INMB in Q3 2020 and has held it in 22 quarters since. The position peaked at $8.72M in Q3 2021. 74 funds tracked by Wall St. Rank hold INMB as of Q4 2025.

  • Vanguard Group held 957,846 shares of INmune Bio worth $1.49M as of Q4 2025.
  • Vanguard Group bought 81,554 INmune Bio shares in Q4 2025, an estimated $146K.
  • INmune Bio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3654 holding.
  • Vanguard Group first reported a position in INmune Bio in Q3 2020 and has held it in 22 quarters since.
  • Vanguard Group's INmune Bio position peaked at $8.72M in Q3 2021.
  • 74 funds tracked by Wall St. Rank held INmune Bio as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.